News >

Ofatumumab Combo Falls Short in Indolent Non-Hodgkin Lymphoma

Jason M. Broderick @jasoncology
Published: Thursday, May 24, 2018

Jan van de Winkel, PhD

Jan van de Winkel, PhD
Adding ofatumumab (Arzerra) to bendamustine (Treanda) failed to improve progression-free survival (PFS) in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) who did not respond to rituximab (Rituxan) monotherapy or a rituximab-containing regimen, missing the primary endpoint of the phase III COMPLEMENT A+B trial. 

The ORRs in the follicular lymphoma, SLL, and marginal zone lymphoma groups were 41%, 68%, and 33%, respectively. The median duration of response was 9.9 months. At a median follow-up of 11.5 months, the median OS in the entire iNHL population was 18.4 months and the median PFS was 8.4 months.

References

  1. Noy A, de Vos S. Thieblemont C, et al. Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study. Presented at: ASH 2016 Annual Meeting. Abstract 1213.
  2. Verastem submits new drug application to US FDA for duvelisib for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. Verastem. Published February 7, 2018, Accessed April 9, 2018. http://bit.ly/2GT3m2u.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x